Bristol Myers’ cell therapy chief Lynelle Hoch explains the reagent behind its autoimmune CAR-T pause and a puzzling MS trial ...
Al Sandrock is calling it quits as CEO of Voyager Therapeutics in the first quarter next year, but he will stay on the board.
The Swiss pharma is teaming up with Zymeworks, paying $55 million upfront for worldwide rights to a trispecific T cell ...
Biopharma M&A, licensing upfronts and VC all cooled in Q3, DealForma data show, while China’s share of pharma in-licensing kept climbing.
Alnylam & Regeneron's siRNA therapy brezosiran reduced mutant huntingtin protein 60-64% in 9 patients, spurring plans for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results